It is tempting to speculate that targeting the TREM-2 pathway could be used as a novel strategy for modulating C1q production and pulmonary innate immune responses, which might be of relevance to other respiratory tract infections and possibly autoimmune diseases. The gene discussed is TREM2; the disease is autoimmune disease.